LY-290181

N/A

Report date: 2022/08/24 20:00:31
NME

Base Information

Drug NameLY-290181
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMetalloproteases inhibitorsProtein kinase C inhibitorsDNA synthesis inhibitors
TargetsMetalloproteasesProtein kinase C
Therapy Area/IndicationsDiabetic AngiopathiesMyocardial IschemiaRheumatic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDiabetic AngiopathiesMyocardial IschemiaRheumatic Diseases

Other Information

ATC CodeN/A
Related LinksN/A